Banco Santander Reveals $34.6M+ in Abbott, AbbVie Holdings

TL;DR

**Santander's Q4 2023 13F shows big bets on healthcare giants Abbott and AbbVie.**

AI Summary

Banco Santander, S.A. filed its 13F-HR on February 9, 2024, revealing its U.S. equity holdings as of December 31, 2023. The filing shows significant positions in major U.S. companies, including 130,179 shares of Abbott Labs valued at $14,328,803 and 131,005 shares of AbbVie Inc. valued at $20,301,845. This matters to investors because it provides transparency into how a major global bank is allocating its U.S. investment capital, potentially signaling confidence or caution in specific sectors or companies.

Why It Matters

This filing offers a glimpse into Banco Santander's investment strategy, allowing individual investors to see which U.S. stocks a major financial institution is holding, which can influence their own investment decisions.

Risk Assessment

Risk Level: low — This is a routine disclosure filing, not an event that inherently carries significant risk for the company or its investors.

Analyst Insight

Investors should review the full list of holdings in the 13F to understand the breadth of Banco Santander's U.S. equity strategy and potentially identify companies that a major institutional investor finds attractive.

Key Numbers

• $14,328,803 — Abbott Labs holding value (Represents a significant portion of Banco Santander's U.S. equity portfolio as of December 31, 2023.)
• 130,179 SH — Abbott Labs shares held (Indicates the number of shares Banco Santander held in Abbott Labs.)
• $20,301,845 — AbbVie Inc. holding value (Represents another substantial investment in Banco Santander's U.S. equity portfolio as of December 31, 2023.)
• 131,005 SH — AbbVie Inc. shares held (Indicates the number of shares Banco Santander held in AbbVie Inc.)
• 20231231 — Conformed Period of Report (This is the date to which the reported holdings apply, providing a snapshot of the portfolio at year-end.)

Key Players & Entities

• Banco Santander, S.A. (company) — the filer of the 13F-HR
• Jose Galiana Guiu (person) — Deputy Chief Accounting Officer who signed the filing
• Abbott Labs (company) — a significant holding of Banco Santander
• AbbVie Inc. (company) — a significant holding of Banco Santander
• $14,328,803 (dollar_amount) — value of Banco Santander's Abbott Labs holding
• $20,301,845 (dollar_amount) — value of Banco Santander's AbbVie Inc. holding

Forward-Looking Statements

• Banco Santander will likely maintain significant positions in large-cap pharmaceutical companies like Abbott Labs and AbbVie Inc. in its next 13F filing. (Banco Santander, S.A.) — medium confidence, target: Q1 2024 13F filing (May 2024)

FAQ

Filing Documents

• primary_doc.html (13F-HR)
• primary_doc.xml (13F-HR) — 4KB
• information_table.html (INFORMATION TABLE)
• information_table.xml (INFORMATION TABLE) — 296KB
• 0000891478-24-000022.txt ( ) — 301KB

From the Filing

SEC FORM 13F-HR The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F COVER PAGE OMB APPROVAL OMB Number: 3235-0006 Estimated average burden hours per response: 23.8 Report for the Calendar Year or Quarter Ended: 12-31-2023 Check here if Amendment    Amendment Number: This Amendment (Check only one.):    is a restatement.    adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Banco Santander, S.A. Address: Ciudad Grupo Santander Boadilla del Monte Madrid , U3   28660 Form 13F File Number: 028-04177 CRD Number (if applicable): 001-12518 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Jose Galiana Guiu Title: Deputy Chief Accounting Officer Phone: 034-615900262 Signature, Place, and Date of Signing: /s/ Jose Galiana Guiu Madrid ,  U3 02-07-2024 [Signature] [City, State] [Date] Report Type (Check only one.): X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)    13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)    13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F Summary Page Report Summary: Number of Other Included Managers: 5 Form 13F Information Table Entry Total: 763 Form 13F Information Table Value Total: 8,462,330,667 (round to nearest dollar) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. [If there are no entries in this list, state “NONE” and omit the column headings and list entries.] No. Name Form 13F File No. CRD No. (if applicable) SEC File No. (if applicable) CIK 1 Banco Santander International SA 028-17923 2 Banco Santander International 028-17917 3 SAM Investment Holdings, S.L. 028-18759 4 Grupo Empresarial Santander, S.L. 028-20720 5 Banco Santander Mexico S.A., Institucion de Banca Multiple, Grupo Financiero Santander Mexico 028-17978   000-55899

View Full Filing

View this 13F-HR filing on SEC EDGAR